Covid-19: Vaccinations

Baroness Laing of Elderslie Excerpts

Monday 11th January 2021 Commons Chamber

[Nadhim Zahawi]

I am grateful for the hon. Member’s backing and support. He asks a number of important questions, and I will attempt to answer them now. Suffice it to say that it would be sensible for us to recognise that test and trace now delivers 85% of those who are tested positive in terms of identifying their direct contacts and the indirect contacts at between 92% and 96%. Over 5 million people have been tested and isolated and are therefore not transmitting or spreading this virus, and 55 million people have been tested. That is a pretty major undertaking, with capacity now touching 770,000 and tests running at about 600,000 a day. From a standing start of about 2,000 a day back in March, that is a pretty remarkable achievement for NHS test and trace.

The hon. Gentleman asked about 24-hour provision. There are two priorities for the NHS, and we have looked really long and hard at this. Priority No. 1 is obviously to target very closely those four most vulnerable categories. Priority No. 2 is to try to get a vaccination to them as quickly as possible, which is about throughput. This is linked because if we were to go to a 24-hour regime, it would be much harder to target the vaccine at those four cohorts. Obviously, when we have limited vaccine volume, we do not want staff standing around waiting for people in centres that are open 24 hours. Also, many of those people are over 80, and we are going into care homes to vaccinate the residents of those homes. The decision to go from 8 to 8 was made because we want to ensure that there is an even spread and very close targeting.

That is linked to throughput—how many vaccinations can we get into people’s arms as quickly as possible? We do not want vaccines sitting in fridges or on shelves. That goes to the hon. Gentleman’s question on the 24 hours, but also the pharmacy question. All the 200 pharmacies that we are operationalising can do 1,000-plus vaccinations a week, so the focus in phase 1, certainly with the first four categories—and, I think, with the total nine categories—is very much on targeting and throughput. The 2,700 sites are the best way that we can target that. Obviously, primary care is very good at identifying those who are most vulnerable or over 80 and, of course, getting into care homes, hence why the NHS plan and the plan we have published today are very much based around those priorities.

As we enter phase 2, where we begin to want to vaccinate as many adults as quickly as possible, we want convenience of course. We want to be able to go into many more pharmacies, so people can walk to their local pharmacy, or GP, and get their jab, when we have limitless volumes of vaccines. We have clearly now got that optioned and it will come through in the weeks and months ahead. That is the reason for that. The hon. Gentleman is absolutely right: the limiting factor continues at this stage to be vaccine volumes. The NHS has built an infrastructure that can deploy the vaccine as quickly as possible, but it is vaccine volumes that will change. With any new manufacturing process, especially one where we are dealing with quite a complex process—it is a biological compound that we are producing—it tends to be lumpy at the start, but it very quickly stabilises and becomes much more even. We are beginning to see that, which is good news.

We are absolutely committed to making sure the health and social care workforce are vaccinated as quickly as possible, and of course we are committed to making sure the residents of care homes are vaccinated by the end of this month—January. I reaffirm that commitment to the hon. Gentleman.

I think the hon. Gentleman’s final question was on data. I am glad that he agrees that it is important, because the Prime Minister’s absolute instruction to us as a team is that we have to make sure we publish as much data as possible as quickly as possible, hence why we have moved to a rhythm of daily data and on the Thursday more detailed publication, which will have regional breakdowns. The NHS is committed as it builds up more data to publish more and more. The nation expects, and rightly wants to see, the speed and the targeting that we are delivering, but I am confident that the NHS has a solid plan. We have the volunteers and the Army—two great institutions of this country—delivering this campaign and with the support of Her Majesty’s Opposition I am sure we will do this.

[Madam Deputy Speaker (Dame Eleanor Laing)]

We now go to the Chairman of the Health and Social Care Committee, Jeremy Hunt.

[Jeremy Hunt (South West Surrey) (Con) [V]]

I congratulate the Minister on getting this programme off to a flying start: to vaccinate 2 million people, including a third of over-80s, six weeks after the first dose was approved is an extraordinary achievement unmatched by any similar country. May I ask him about the speed of the roll-out? Many people want teachers to be jabbed as quickly as possible, but is it the case that all those in groups 1 to 4 will need their second jabs before we can make real inroads into other key groups? And will he publish the breakdown of numbers vaccinated not just by region but by local authority area, because a lot of people would like to know just how many people have been vaccinated in their local area?

--- Later in debate ---

[Nadhim Zahawi]

There is a lot to unpack there; let me try to take the points in reverse. We can guarantee that those who have had their Pfizer vaccine will get their booster within the prescribed period of up to 12 weeks. The hon. Lady asked about those who have had a second jab already. Information went out to primary care networks and hospital hubs, saying that those who have an appointment up to 4 January should be able to have their appointment honoured. Beyond that, they have been working very closely with the NHS England team centrally, which we have been supporting with resources and actually phoning to postpone those appointments further; hence why we have protected many more people.

It is worth reminding the House that for every 250 people from the most vulnerable cohorts that we protect, we save a life. For every 20 people in care homes that we vaccinate, we save a life. The focus is therefore now very much on care homes. We began with the Pfizer vaccine into care homes. Of course, last week—on 4 January—we started to roll out the AstraZeneca vaccine, which is much easier to administer into care homes, especially for the roving teams. It had to spend two days in hospitals before it was released to primary care networks, but the moment it was released, it went into care homes and now some areas in England. We have about 10,000 care homes where we have to vaccinate residents and, of course, those who look after them. Some have done their care homes already; others are beginning to do the same thing. All will be done by the end of the month.

The hon. Lady talked about people having to travel long distances. I mentioned in my opening statement about the strategy that there will be 2,700 vaccination sites. I think she may have been confused about the figure of 1,200, which is the number of primary care networks, hospital hubs and large vaccination centres, but there will be 2,700 vaccination sites. By the end of the month, no one will be more than 10 miles away from a vaccination site.

[Madam Deputy Speaker (Dame Eleanor Laing)]

I thank the Minister for being so assiduous in giving very thorough answers to the long and complicated series of questions that have already been put to him, but I must say to the House that we now have half an hour more for the rest of this statement, so I insist on having questions, not statements, from everyone. I specifically mention this to people who are coming in virtually, because they seem to lose a sense of timing when they are not here in the Chamber. A question means a question—just one question. I say to the Minister, who has been most assiduous, that where he has already given an answer to the question, I will not insist that he has to give the answer again because the person who is now asking it has not listened to his first answer.

[Bob Stewart (Beckenham) (Con)]

I will be as quick as I can, Madam Deputy Speaker.

Some of my Beckenham constituents have contacted me to say that they think they should have had the vaccination already; two of them are in their 90s, so I am slightly alarmed. I am told that GPs are not necessarily the people to go to in order to ask what is happening, so I wonder who my constituents and I should go to when the system—inadvertently, perhaps—does not actually give out an appointment that it might have done.

--- Later in debate ---

[Nadhim Zahawi]

I commend the Israeli Government and health service for a stellar job in vaccinating their most vulnerable communities. We have a lot to learn from other countries, including the throughput—the speed at which they manage to vaccinate—which is something from which we can all learn so that we can improve our output. NHS England and the teams on the frontline have been doing a tremendous job and is worth us all thinking about that: we stand on the shoulders of real heroes.

[Madam Deputy Speaker (Dame Eleanor Laing)]

We are way over time, so I am going to take only four more questions and I would be grateful if they could be swift.

[Jeremy Wright (Kenilworth and Southam) (Con) [V]]

I congratulate my hon. Friend on the progress made so far, but ask him for some reassurance about those whose appointments have been cancelled due to the vaccine unexpectedly not being available. Will he confirm that they will not be forgotten about, that they will not lose their place in the queue and that they will be reached swiftly?

--- Later in debate ---

[Nadhim Zahawi]

It is not our capacity, but the manufacturers’; AstraZeneca produces the Oxford vaccine, and Pfizer-BioNTech produce their vaccine, and Moderna’s is now also approved and in process. There are a number of processes throughout the manufacturing process. When we go from the bulk vaccine into fill and finish, there is a period of time and a sterility test the vaccines have to go through. Then there is batch testing by both the manufacturer and the regulator. All of that gets better and better every single day. It is a new manufacturing process. Oxford-AstraZeneca are delivering 100 million vaccines, which is what we have bought from them, and we have bought 40 million from Pfizer. We will have millions of vaccines in the weeks and months to come. We will meet our target of mid February for delivering the opportunity of a vaccine to the four cohorts most vulnerable to covid.

[Madam Deputy Speaker (Dame Eleanor Laing)]

I thank the Minister. I am sorry to the nine colleagues who have not been called to ask their questions. I hope they will encourage their colleagues to ask shorter questions in future, because that is how we will manage to be fairer in getting more people in.